{"id":358917,"date":"2025-08-30T07:05:31","date_gmt":"2025-08-30T07:05:31","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-atricure\/"},"modified":"2025-08-30T07:05:31","modified_gmt":"2025-08-30T07:05:31","slug":"how-to-buy-atricure","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-atricure\/","title":{"rendered":"AtriCure, Inc. (ATRC) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; AtriCure, Inc. (ATRC) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334045,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-358917","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"AtriCure, Inc. (ATRC) Hisseleri Nas\u0131l Al\u0131n\u0131r - AtriCure, Inc. (ATRC) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"AtriCure, Inc. (ATRC) Hisseleri Nas\u0131l Al\u0131n\u0131r - AtriCure, Inc. (ATRC) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"AtriCure, Inc. (ATRC) hisselerini mevcut fiyat, riskler ve b\u00fcy\u00fcme potansiyeli konusunda uzman analizleriyle nas\u0131l alaca\u011f\u0131n\u0131z\u0131 \u00f6\u011frenin. 2025'te neden medikal cihaz hisselerinin y\u00fckseldi\u011fini ke\u015ffedin.","description_source":{"label":"Description","type":"textarea","formatted_value":"AtriCure, Inc. (ATRC) hisselerini mevcut fiyat, riskler ve b\u00fcy\u00fcme potansiyeli konusunda uzman analizleriyle nas\u0131l alaca\u011f\u0131n\u0131z\u0131 \u00f6\u011frenin. 2025'te neden medikal cihaz hisselerinin y\u00fckseldi\u011fini ke\u015ffedin."},"intro":"\u0130leri teknoloji medikal teknolojiye yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? AtriCure, kalp cerrahisi inovasyonunun gelece\u011fini temsil ediyor\u2014literat\u00fcrde kalpleri kurtaran ve portf\u00f6y\u00fcn\u00fcz\u00fc b\u00fcy\u00fctme potansiyeline sahip bir \u015firket. \u00c7\u0131\u011f\u0131r a\u00e7an klinik deneyler ve artan gelirlerle, bu sadece ba\u015fka bir biyoteknoloji hissesi de\u011fil; hasta bak\u0131m\u0131n\u0131 d\u00fcnya \u00e7ap\u0131nda d\u00f6n\u00fc\u015ft\u00fcren 50 milyar dolarl\u0131k kalp cihazlar\u0131 pazar\u0131nda bir oyundur.","intro_source":{"label":"Intro","type":"text","formatted_value":"\u0130leri teknoloji medikal teknolojiye yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? AtriCure, kalp cerrahisi inovasyonunun gelece\u011fini temsil ediyor\u2014literat\u00fcrde kalpleri kurtaran ve portf\u00f6y\u00fcn\u00fcz\u00fc b\u00fcy\u00fctme potansiyeline sahip bir \u015firket. \u00c7\u0131\u011f\u0131r a\u00e7an klinik deneyler ve artan gelirlerle, bu sadece ba\u015fka bir biyoteknoloji hissesi de\u011fil; hasta bak\u0131m\u0131n\u0131 d\u00fcnya \u00e7ap\u0131nda d\u00f6n\u00fc\u015ft\u00fcren 50 milyar dolarl\u0131k kalp cihazlar\u0131 pazar\u0131nda bir oyundur."},"body_html":"<h2>\ud83d\udcc8 AtriCure Hissesi: G\u00fcncel Fiyat ve Kritik Tarihler<\/h2> <p>30 A\u011fustos 2025 itibar\u0131yla, AtriCure, Inc. (ATRC) NASDAQ'da <strong>37,87 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor. Ancak takviminize i\u015faretleyin\u2014<strong>4 Kas\u0131m 2025<\/strong> bir sonraki b\u00fcy\u00fck fiyat hareketi f\u0131rsat\u0131n\u0131z. Bu tarihte AtriCure, piyasa kapan\u0131\u015f\u0131ndan sonra 3. \u00e7eyrek kazan\u00e7lar\u0131n\u0131 a\u00e7\u0131klayacak ve ge\u00e7mi\u015fte bu raporlar\u0131n hisse senedi \u00fczerinde \u00f6nemli etkileri olmu\u015ftur.<\/p> <h3>Kazan\u00e7 Etkisi Analizi: ATRC Haberlerine Nas\u0131l Tepki Veriyor<\/h3> <p>AtriCure hissesi, her ak\u0131ll\u0131 yat\u0131r\u0131mc\u0131n\u0131n anlamas\u0131 gereken bir kazan\u00e7lar etraf\u0131nda geli\u015fen bir model olu\u015fturdu. 29 Temmuz 2025'teki son 2. \u00e7eyrek raporu tam olarak zamanlaman\u0131n neden \u00f6nemli oldu\u011funu g\u00f6sterdi:<\/p> <p><strong>2025 2. \u00c7eyrek Performans\u0131:<\/strong><\/p> <ul> <li>Gelir: 136,14 Milyon $ (tahminleri 6 Milyon $ a\u015ft\u0131)<\/li> <li>Hisse Ba\u015f\u0131na Kazan\u00e7 (EPS): -0,02 $ (beklentiler -0,15 $ iken \u00e7ok daha iyi)<\/li> <li>Sonu\u00e7: Hisse sonraki g\u00fcnlerde %5,6 y\u00fckseldi<\/li> <\/ul> <p>Model a\u00e7\u0131k\u2014AtriCure beklentileri a\u015ft\u0131\u011f\u0131nda, piyasa bunu c\u00f6mert\u00e7e \u00f6d\u00fcllendiriyor. \u015eirket, tam y\u0131l rehberli\u011fini 527-533 Milyon $ olarak y\u00fckseltti ve y\u00f6netimin devam eden ivmeye olan g\u00fcvenini g\u00f6steriyor.<\/p> <p>Tarihsel kazan\u00e7 tepkileri tutarl\u0131 modeller g\u00f6steriyor:<\/p> <ul> <li><strong>Olumlu s\u00fcrprizler<\/strong> \u2192 %5-8 anl\u0131k kazan\u00e7lar<\/li> <li><strong>Rehberlik y\u00fckseltmeleri<\/strong> \u2192 2-3 haftal\u0131k s\u00fcrd\u00fcr\u00fclebilir ralliler<\/li> <li><strong>Klinik deney g\u00fcncellemeleri<\/strong> \u2192 uzun vadeli y\u00fckseli\u015fle volatilite<\/li> <\/ul> <h3>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu: M\u00fccadeleden G\u00fcce<\/h3> <p>AtriCure hissesi tam bir h\u0131z treni oldu\u2014ancak son zamanlarda \u00e7o\u011funlukla y\u00fckseliyor. Mart'tan A\u011fustos 2025'e neler oldu:<\/p> <p><strong>Mart 2025:<\/strong> 28-30 $ civar\u0131nda i\u015flem g\u00f6r\u00fcyordu, y\u0131l\u0131n zor ba\u015flang\u0131c\u0131ndan sonra dengelenmeye \u00e7al\u0131\u015f\u0131yordu. Yat\u0131r\u0131mc\u0131lar medikal cihaz harcamalar\u0131nda temkinliydi.<\/p> <p><strong>May\u0131s 2025:<\/strong> Hisse kritik destek seviyesi olan 29 $ a ula\u015ft\u0131, ancak sonra bir \u015fey de\u011fi\u015fti. 1. \u00e7eyrek kazan\u00e7lar\u0131 %13,6 gelir art\u0131\u015f\u0131 g\u00f6sterdi ve momentum olu\u015fmaya ba\u015flad\u0131.<\/p> <p><strong>Temmuz 2025:<\/strong> 2. \u00e7eyrek kazan\u00e7lar\u0131 bomba gibi d\u00fc\u015ft\u00fc\u2014%17,1 gelir art\u0131\u015f\u0131 ve b\u00fcy\u00fck EPS s\u00fcrprizi. Hisse birka\u00e7 g\u00fcn i\u00e7inde 34 $ dan 37 $ \u00fczerine s\u0131\u00e7rad\u0131.<\/p> <p><strong>A\u011fustos 2025:<\/strong> Yat\u0131r\u0131mc\u0131lar kazan\u00e7lar\u0131 sindirirken ve 3. \u00e7eyre\u011fe bakarken 37-38 $ civar\u0131nda konsolidasyon.<\/p> <p>Genel trend? <strong>May\u0131s diplerinden itibaren %25-30 etkileyici bir y\u00fckseli\u015f<\/strong>. Medikal cihaz sekt\u00f6r\u00fc \u0131s\u0131n\u0131yor ve AtriCure bu dalgay\u0131 m\u00fckemmel \u015fekilde s\u00fcr\u00fcyor.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>Mevcut analist konsens\u00fcs\u00fc ve \u015firket ivmesine dayanarak, ak\u0131ll\u0131 paran\u0131n beklentileri \u015funlar:<\/p> <p><strong>2025 Y\u0131l Sonu:<\/strong> 43-45 $ (mevcut seviyelerden %15-20 y\u00fckseli\u015f) \u2192 <strong>G\u00dc\u00c7L\u00dc AL<\/strong><br> Y\u00fckseltilmi\u015f rehberlik, ba\u015far\u0131l\u0131 \u00fcr\u00fcn lansmanlar\u0131 ve 6.500 hastal\u0131 dev klinik deney tamamlanmas\u0131 y\u0131l sonu ivmesi i\u00e7in m\u00fckemmel ko\u015fullar yarat\u0131yor.<\/p> <p><strong>2026 Tahmini:<\/strong> 50-55 $<br> Needham, Oppenheimer ve Stifel analistleri bu aral\u0131kta hedefler belirledi. Pulsed Field Ablation platformu o zamana kadar klinik deneylerde olmal\u0131, ek heyecan yaratacak.<\/p> <p><strong>2028 Projeksiyonu:<\/strong> 65-75 $<br> Bu noktada uluslararas\u0131 geni\u015fleme tam h\u0131zda olmal\u0131 ve cryoXT Probe gibi yeni \u00fcr\u00fcnler gelire anlaml\u0131 katk\u0131 sa\u011flayacak.<\/p> <p><strong>2030 Vizyonu:<\/strong> 80-100 $<br> Burada yapay zeka destekli modeller, uygulama g\u00fc\u00e7l\u00fc kal\u0131r ve pazar benimsemesi h\u0131zlanmaya devam ederse hissenin potansiyelini g\u00f6steriyor.<\/p> <p><strong>Karar:<\/strong> Bu spek\u00fclatif bir biyoteknoloji oyunu de\u011fil\u2014kan\u0131tlanm\u0131\u015f \u00fcr\u00fcnleri ve h\u0131zlanan b\u00fcy\u00fcmesi olan ticari a\u015famadaki bir \u015firket. <strong>AL<\/strong> hem k\u0131sa vadeli ticaret f\u0131rsatlar\u0131 hem de uzun vadeli b\u00fcy\u00fcme i\u00e7in.<\/p> <h2>\u26a0\ufe0f Yat\u0131r\u0131m Riskleri: Neler Yanl\u0131\u015f Gidebilir?<\/h2> <p>Her yat\u0131r\u0131m\u0131n riskleri vard\u0131r ve AtriCure istisna de\u011fil. \u0130\u015fte deneyimli yat\u0131r\u0131mc\u0131lar\u0131 uykusuz b\u0131rakanlar:<\/p> <h3>Reg\u00fclasyon Ruleti<\/h3> <p>FDA, AtriCure'un kaderini kontrol ediyor. Herhangi bir d\u00fczenleyici de\u011fi\u015fiklik veya onay gecikmesi hisseyi vurabilir. Unutmay\u0131n\u2014medikal cihazlar d\u00fczenleyici kararlara ba\u011fl\u0131d\u0131r.<\/p> <h3>Teknoloji Bozucu Etkiler<\/h3> <p>Medtronic ve Boston Scientific gibi devlerin Pulsed Field Ablation kateterleri varolu\u015fsal tehdit olu\u015fturuyor. Bu teknolojiler \u00fcst\u00fcn \u00e7\u0131karsa, AtriCure'un cerrahi yakla\u015f\u0131m\u0131 modas\u0131 ge\u00e7mi\u015f olabilir.<\/p> <h3>Uygulama Riski<\/h3> <p>527-533 Milyon $ olarak y\u00fckseltilen rehberlik? Kusursuz uygulama varsay\u0131yor. \u00dcretim, sat\u0131\u015f g\u00fcc\u00fc geni\u015flemesi veya \u00fcr\u00fcn lansmanlar\u0131nda herhangi bir hata ciddi d\u00fc\u015f\u00fc\u015flere yol a\u00e7abilir.<\/p> <h3>De\u011ferleme Endi\u015feleri<\/h3> <p>K\u00e2r etmeyen bir \u015firket olarak kazan\u00e7lara g\u00f6re y\u00fcksek \u00e7arpanlarda i\u015flem g\u00f6r\u00fcyor, b\u00fcy\u00fcme yava\u015flarsa \u00e7arpan s\u0131k\u0131\u015fmas\u0131 ve keskin fiyat d\u00fc\u015f\u00fc\u015fleri olabilir.<\/p> <h2>\ud83d\ude80 Olumlu Sinyaller: Bo\u011falar\u0131n Neden G\u00fcrledi\u011fi<\/h2> <p>Ancak sadece risk yok\u2014i\u015fte ak\u0131ll\u0131 paran\u0131n ATRC'ye neden y\u00fcklendi\u011fi:<\/p> <h3>Klinik Deney B\u00fcy\u00fck Ba\u015far\u0131s\u0131<\/h3> <p>6.500 hastal\u0131 LeAAPS deneyi \u015fimdiye kadar yap\u0131lm\u0131\u015f en b\u00fcy\u00fck kalp cerrahisi cihaz deneyi. Olumlu sonu\u00e7lar y\u0131lda 1 milyondan fazla ek hasta pazar\u0131n\u0131 a\u00e7abilir.<\/p> <h3>Mali Momentum<\/h3> <p>%17,1 gelir art\u0131\u015f\u0131 sadece iyi de\u011fil\u2014medikal cihaz \u015firketi i\u00e7in ola\u011fan\u00fcst\u00fc. Daha da iyisi? Br\u00fct marjlar %74,9'a ula\u015ft\u0131 ve d\u00fczeltilmi\u015f FAV\u00d6K y\u0131ll\u0131k 7,6 Milyon $ artt\u0131.<\/p> <h3>\u00dcr\u00fcn \u0130novasyon Hatt\u0131<\/h3> <p>AtriClip\u00ae FLEX-Mini\u2122 h\u0131zla benimseniyor ve Pulsed Field Ablation platformu kateter bazl\u0131 rakiplere kar\u015f\u0131 potansiyel oyun de\u011fi\u015ftirici.<\/p> <h3>Analist Sevgi Festivali<\/h3> <p>Hisseyi takip eden 9 analist\u20148 G\u00fc\u00e7l\u00fc Al, 1 Al. Ortalama fiyat hedefi 49,60 $ ve %33 y\u00fckseli\u015f potansiyeli. En son ne zaman bu kadar konsens\u00fcs g\u00f6rd\u00fcn\u00fcz?<\/p> <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <p>T\u00fcm bu verileri analiz ettikten sonra i\u015fte eylem plan\u0131n\u0131z:<\/p> <ol> <li><strong>Ortalama Maliyetle Al\u0131m Yap\u0131n<\/strong> - M\u00fckemmel giri\u015f zaman\u0131n\u0131 yakalamaya \u00e7al\u0131\u015fmay\u0131n. K\u00fc\u00e7\u00fck bir pozisyonla ba\u015flay\u0131n ve 37 $ alt\u0131ndaki d\u00fc\u015f\u00fc\u015flerde ekleme yap\u0131n.<\/li> <li><strong>Kazan\u00e7 Uyar\u0131lar\u0131 Ayarlay\u0131n<\/strong> - Takviminize 4 Kas\u0131m'\u0131 i\u015faretleyin. Kazan\u00e7lar\u0131n tekrar beklentileri a\u015faca\u011f\u0131na inan\u0131yorsan\u0131z, kazan\u00e7 \u00f6ncesi al\u0131m yapmay\u0131 d\u00fc\u015f\u00fcn\u00fcn.<\/li> <li><strong>Pozisyon B\u00fcy\u00fckl\u00fc\u011f\u00fcn\u00fc Y\u00f6netin<\/strong> - Bu hala volatilitesi olan bir medikal cihaz hissesi. Toplam portf\u00f6y\u00fcn\u00fcz\u00fcn %5-10'u ile s\u0131n\u0131rlay\u0131n.<\/li> <li><strong>Esprili Ger\u00e7eklik Kontrol\u00fc<\/strong>: \"ATRC ticareti kalp cerrahisi gibidir\u2014sakin eller kazan\u0131r. Normal volatilite s\u0131ras\u0131nda panik sat\u0131\u015f\u0131, kan g\u00f6rd\u00fc\u011f\u00fcn\u00fcz i\u00e7in ameliyathaneden ka\u00e7mak gibidir.\"<\/li> <\/ol> <h2>\u2705 AtriCure, Inc. (ATRC) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <p>Bu yenilik\u00e7i medikal \u015firketi portf\u00f6y\u00fcn\u00fcze eklemeye haz\u0131r m\u0131s\u0131n\u0131z? \u0130\u015fte basit s\u00fcreciniz:<\/p> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Platformunuzu Se\u00e7in<\/td><td>NASDAQ hisselerini sunan ve makul komisyon \u00fccretlerine sahip oldu\u011fundan emin olun<\/td><\/tr> <tr><td>2<\/td><td>Hesab\u0131n\u0131z\u0131 Fonlay\u0131n<\/td><td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n\u2014100 $ bile ba\u015flaman\u0131z i\u00e7in yeterli<\/td><\/tr> <tr><td>3<\/td><td>\"ATRC\" Aray\u0131n<\/td><td>Sadece \u015firket ad\u0131 de\u011fil, sembol\u00fc kullan\u0131n<\/td><\/tr> <tr><td>4<\/td><td>Emir T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td><td>Giri\u015f fiyat\u0131n\u0131z\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n\u2014\u015fimdi al\u0131yorsan\u0131z yakla\u015f\u0131k 37,50 $ olarak ayarlay\u0131n<\/td><\/tr> <tr><td>5<\/td><td>\u0130nceleyin ve Onaylay\u0131n<\/td><td>Emir detaylar\u0131n\u0131 ve \u00fccretleri son kez kontrol edin<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Pocket Option ATRC Ticareti \u0130\u00e7in Neden Mant\u0131kl\u0131?<\/h2> <p>AtriCure gibi yenilik\u00e7i \u015firketlerde pozisyon olu\u015fturmak isteyen yeni yat\u0131r\u0131mc\u0131lar i\u00e7in Pocket Option, bu stratejiyle m\u00fckemmel uyum sa\u011flayan birka\u00e7 avantaj sunar:<\/p> <p><strong>Minimum Para Yat\u0131rma Sadece 5 $<\/strong> - ATRC pozisyonunuzu minimum sermaye riskiyle olu\u015fturmaya ba\u015flayabilirsiniz, b\u00fcy\u00fck miktarlara ge\u00e7meden \u00f6nce yat\u0131r\u0131m tezini test etmek i\u00e7in ideal.<\/p> <p><strong>\u015eim\u015fek H\u0131z\u0131nda Do\u011frulama<\/strong> - Tek bir belge y\u00fckleyin ve dakikalar i\u00e7inde i\u015flem yapmaya ba\u015flay\u0131n, g\u00fcnler de\u011fil. Kazan\u00e7lar 4 Kas\u0131m'da a\u00e7\u0131klanacakken h\u0131z \u00f6nemlidir.<\/p> <p><strong>Esnek Para \u00c7ekme Se\u00e7enekleri<\/strong> - Kripto paralar, e-c\u00fczdanlar ve geleneksel bankac\u0131l\u0131k dahil y\u00fczlerce \u00e7ekim y\u00f6ntemiyle, ATRC analist hedeflerine ula\u015ft\u0131\u011f\u0131nda kolayca kar alabilirsiniz.<\/p> <p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc, medikal sekt\u00f6r haberleri ve kazan\u00e7 duyurular\u0131n\u0131 takip etmenize yard\u0131mc\u0131 olan ger\u00e7ek zamanl\u0131 grafikler ve uyar\u0131larla ATRC pozisyonunuzu izlemenizi kolayla\u015ft\u0131r\u0131r.<\/p> <h2>\ud83c\udf0d 2025'te AtriCure: Kalp \u0130novasyon Lideri<\/h2> <p>AtriCure sadece ba\u015fka bir medikal \u015firket de\u011fil\u2014d\u00fcnyan\u0131n d\u00f6rt bir yan\u0131ndaki doktorlar\u0131n kalp rahats\u0131zl\u0131klar\u0131n\u0131 tedavi etme \u015feklini devrim niteli\u011finde de\u011fi\u015ftiriyor. \u015eirket, kalp dokusunun cerrahi ablasyonu, sol atriyal apendiks y\u00f6netimi ve ameliyat sonras\u0131 a\u011fr\u0131 kontrol\u00fc i\u00e7in \u00e7\u0131\u011f\u0131r a\u00e7an cihazlar geli\u015ftiriyor.<\/p> <p>\u00d6nde gelen \u00fcr\u00fcnleri aras\u0131nda kalp aritmileri i\u00e7in Isolator Synergy Kelep\u00e7eleri, cryoICE Cryoablasyon Sistemi ve \u015fu anda \u015fimdiye kadar yap\u0131lm\u0131\u015f en b\u00fcy\u00fck kalp cerrahisi cihaz deneyi olan AtriClip Sistemi yer al\u0131yor.<\/p> <p><strong>2025 \u0130lgin\u00e7 Ger\u00e7ek:<\/strong> AtriCure'un LeAAPS deneyi 6.500 hasta kaydetti\u201413 Boeing 747 jumbo u\u00e7a\u011f\u0131 dolduracak kadar insan! Bu dev \u00e7al\u0131\u015fma, ameliyat \u00f6ncesi atriyal fibrilasyon tan\u0131s\u0131 olmayan ancak yine de fel\u00e7 riski ta\u015f\u0131yan d\u00fcnya \u00e7ap\u0131nda 1 milyondan fazla kalp cerrahisi hastas\u0131na potansiyel olarak yard\u0131mc\u0131 olabilir.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 AtriCure Hissesi: G\u00fcncel Fiyat ve Kritik Tarihler<\/h2>\n<p>30 A\u011fustos 2025 itibar\u0131yla, AtriCure, Inc. (ATRC) NASDAQ&#8217;da <strong>37,87 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor. Ancak takviminize i\u015faretleyin\u2014<strong>4 Kas\u0131m 2025<\/strong> bir sonraki b\u00fcy\u00fck fiyat hareketi f\u0131rsat\u0131n\u0131z. Bu tarihte AtriCure, piyasa kapan\u0131\u015f\u0131ndan sonra 3. \u00e7eyrek kazan\u00e7lar\u0131n\u0131 a\u00e7\u0131klayacak ve ge\u00e7mi\u015fte bu raporlar\u0131n hisse senedi \u00fczerinde \u00f6nemli etkileri olmu\u015ftur.<\/p>\n<h3>Kazan\u00e7 Etkisi Analizi: ATRC Haberlerine Nas\u0131l Tepki Veriyor<\/h3>\n<p>AtriCure hissesi, her ak\u0131ll\u0131 yat\u0131r\u0131mc\u0131n\u0131n anlamas\u0131 gereken bir kazan\u00e7lar etraf\u0131nda geli\u015fen bir model olu\u015fturdu. 29 Temmuz 2025&#8217;teki son 2. \u00e7eyrek raporu tam olarak zamanlaman\u0131n neden \u00f6nemli oldu\u011funu g\u00f6sterdi:<\/p>\n<p><strong>2025 2. \u00c7eyrek Performans\u0131:<\/strong><\/p>\n<ul>\n<li>Gelir: 136,14 Milyon $ (tahminleri 6 Milyon $ a\u015ft\u0131)<\/li>\n<li>Hisse Ba\u015f\u0131na Kazan\u00e7 (EPS): -0,02 $ (beklentiler -0,15 $ iken \u00e7ok daha iyi)<\/li>\n<li>Sonu\u00e7: Hisse sonraki g\u00fcnlerde %5,6 y\u00fckseldi<\/li>\n<\/ul>\n<p>Model a\u00e7\u0131k\u2014AtriCure beklentileri a\u015ft\u0131\u011f\u0131nda, piyasa bunu c\u00f6mert\u00e7e \u00f6d\u00fcllendiriyor. \u015eirket, tam y\u0131l rehberli\u011fini 527-533 Milyon $ olarak y\u00fckseltti ve y\u00f6netimin devam eden ivmeye olan g\u00fcvenini g\u00f6steriyor.<\/p>\n<p>Tarihsel kazan\u00e7 tepkileri tutarl\u0131 modeller g\u00f6steriyor:<\/p>\n<ul>\n<li><strong>Olumlu s\u00fcrprizler<\/strong> \u2192 %5-8 anl\u0131k kazan\u00e7lar<\/li>\n<li><strong>Rehberlik y\u00fckseltmeleri<\/strong> \u2192 2-3 haftal\u0131k s\u00fcrd\u00fcr\u00fclebilir ralliler<\/li>\n<li><strong>Klinik deney g\u00fcncellemeleri<\/strong> \u2192 uzun vadeli y\u00fckseli\u015fle volatilite<\/li>\n<\/ul>\n<h3>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu: M\u00fccadeleden G\u00fcce<\/h3>\n<p>AtriCure hissesi tam bir h\u0131z treni oldu\u2014ancak son zamanlarda \u00e7o\u011funlukla y\u00fckseliyor. Mart&#8217;tan A\u011fustos 2025&#8217;e neler oldu:<\/p>\n<p><strong>Mart 2025:<\/strong> 28-30 $ civar\u0131nda i\u015flem g\u00f6r\u00fcyordu, y\u0131l\u0131n zor ba\u015flang\u0131c\u0131ndan sonra dengelenmeye \u00e7al\u0131\u015f\u0131yordu. Yat\u0131r\u0131mc\u0131lar medikal cihaz harcamalar\u0131nda temkinliydi.<\/p>\n<p><strong>May\u0131s 2025:<\/strong> Hisse kritik destek seviyesi olan 29 $ a ula\u015ft\u0131, ancak sonra bir \u015fey de\u011fi\u015fti. 1. \u00e7eyrek kazan\u00e7lar\u0131 %13,6 gelir art\u0131\u015f\u0131 g\u00f6sterdi ve momentum olu\u015fmaya ba\u015flad\u0131.<\/p>\n<p><strong>Temmuz 2025:<\/strong> 2. \u00e7eyrek kazan\u00e7lar\u0131 bomba gibi d\u00fc\u015ft\u00fc\u2014%17,1 gelir art\u0131\u015f\u0131 ve b\u00fcy\u00fck EPS s\u00fcrprizi. Hisse birka\u00e7 g\u00fcn i\u00e7inde 34 $ dan 37 $ \u00fczerine s\u0131\u00e7rad\u0131.<\/p>\n<p><strong>A\u011fustos 2025:<\/strong> Yat\u0131r\u0131mc\u0131lar kazan\u00e7lar\u0131 sindirirken ve 3. \u00e7eyre\u011fe bakarken 37-38 $ civar\u0131nda konsolidasyon.<\/p>\n<p>Genel trend? <strong>May\u0131s diplerinden itibaren %25-30 etkileyici bir y\u00fckseli\u015f<\/strong>. Medikal cihaz sekt\u00f6r\u00fc \u0131s\u0131n\u0131yor ve AtriCure bu dalgay\u0131 m\u00fckemmel \u015fekilde s\u00fcr\u00fcyor.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>Mevcut analist konsens\u00fcs\u00fc ve \u015firket ivmesine dayanarak, ak\u0131ll\u0131 paran\u0131n beklentileri \u015funlar:<\/p>\n<p><strong>2025 Y\u0131l Sonu:<\/strong> 43-45 $ (mevcut seviyelerden %15-20 y\u00fckseli\u015f) \u2192 <strong>G\u00dc\u00c7L\u00dc AL<\/strong><br \/> Y\u00fckseltilmi\u015f rehberlik, ba\u015far\u0131l\u0131 \u00fcr\u00fcn lansmanlar\u0131 ve 6.500 hastal\u0131 dev klinik deney tamamlanmas\u0131 y\u0131l sonu ivmesi i\u00e7in m\u00fckemmel ko\u015fullar yarat\u0131yor.<\/p>\n<p><strong>2026 Tahmini:<\/strong> 50-55 $<br \/> Needham, Oppenheimer ve Stifel analistleri bu aral\u0131kta hedefler belirledi. Pulsed Field Ablation platformu o zamana kadar klinik deneylerde olmal\u0131, ek heyecan yaratacak.<\/p>\n<p><strong>2028 Projeksiyonu:<\/strong> 65-75 $<br \/> Bu noktada uluslararas\u0131 geni\u015fleme tam h\u0131zda olmal\u0131 ve cryoXT Probe gibi yeni \u00fcr\u00fcnler gelire anlaml\u0131 katk\u0131 sa\u011flayacak.<\/p>\n<p><strong>2030 Vizyonu:<\/strong> 80-100 $<br \/> Burada yapay zeka destekli modeller, uygulama g\u00fc\u00e7l\u00fc kal\u0131r ve pazar benimsemesi h\u0131zlanmaya devam ederse hissenin potansiyelini g\u00f6steriyor.<\/p>\n<p><strong>Karar:<\/strong> Bu spek\u00fclatif bir biyoteknoloji oyunu de\u011fil\u2014kan\u0131tlanm\u0131\u015f \u00fcr\u00fcnleri ve h\u0131zlanan b\u00fcy\u00fcmesi olan ticari a\u015famadaki bir \u015firket. <strong>AL<\/strong> hem k\u0131sa vadeli ticaret f\u0131rsatlar\u0131 hem de uzun vadeli b\u00fcy\u00fcme i\u00e7in.<\/p>\n<h2>\u26a0\ufe0f Yat\u0131r\u0131m Riskleri: Neler Yanl\u0131\u015f Gidebilir?<\/h2>\n<p>Her yat\u0131r\u0131m\u0131n riskleri vard\u0131r ve AtriCure istisna de\u011fil. \u0130\u015fte deneyimli yat\u0131r\u0131mc\u0131lar\u0131 uykusuz b\u0131rakanlar:<\/p>\n<h3>Reg\u00fclasyon Ruleti<\/h3>\n<p>FDA, AtriCure&#8217;un kaderini kontrol ediyor. Herhangi bir d\u00fczenleyici de\u011fi\u015fiklik veya onay gecikmesi hisseyi vurabilir. Unutmay\u0131n\u2014medikal cihazlar d\u00fczenleyici kararlara ba\u011fl\u0131d\u0131r.<\/p>\n<h3>Teknoloji Bozucu Etkiler<\/h3>\n<p>Medtronic ve Boston Scientific gibi devlerin Pulsed Field Ablation kateterleri varolu\u015fsal tehdit olu\u015fturuyor. Bu teknolojiler \u00fcst\u00fcn \u00e7\u0131karsa, AtriCure&#8217;un cerrahi yakla\u015f\u0131m\u0131 modas\u0131 ge\u00e7mi\u015f olabilir.<\/p>\n<h3>Uygulama Riski<\/h3>\n<p>527-533 Milyon $ olarak y\u00fckseltilen rehberlik? Kusursuz uygulama varsay\u0131yor. \u00dcretim, sat\u0131\u015f g\u00fcc\u00fc geni\u015flemesi veya \u00fcr\u00fcn lansmanlar\u0131nda herhangi bir hata ciddi d\u00fc\u015f\u00fc\u015flere yol a\u00e7abilir.<\/p>\n<h3>De\u011ferleme Endi\u015feleri<\/h3>\n<p>K\u00e2r etmeyen bir \u015firket olarak kazan\u00e7lara g\u00f6re y\u00fcksek \u00e7arpanlarda i\u015flem g\u00f6r\u00fcyor, b\u00fcy\u00fcme yava\u015flarsa \u00e7arpan s\u0131k\u0131\u015fmas\u0131 ve keskin fiyat d\u00fc\u015f\u00fc\u015fleri olabilir.<\/p>\n<h2>\ud83d\ude80 Olumlu Sinyaller: Bo\u011falar\u0131n Neden G\u00fcrledi\u011fi<\/h2>\n<p>Ancak sadece risk yok\u2014i\u015fte ak\u0131ll\u0131 paran\u0131n ATRC&#8217;ye neden y\u00fcklendi\u011fi:<\/p>\n<h3>Klinik Deney B\u00fcy\u00fck Ba\u015far\u0131s\u0131<\/h3>\n<p>6.500 hastal\u0131 LeAAPS deneyi \u015fimdiye kadar yap\u0131lm\u0131\u015f en b\u00fcy\u00fck kalp cerrahisi cihaz deneyi. Olumlu sonu\u00e7lar y\u0131lda 1 milyondan fazla ek hasta pazar\u0131n\u0131 a\u00e7abilir.<\/p>\n<h3>Mali Momentum<\/h3>\n<p>%17,1 gelir art\u0131\u015f\u0131 sadece iyi de\u011fil\u2014medikal cihaz \u015firketi i\u00e7in ola\u011fan\u00fcst\u00fc. Daha da iyisi? Br\u00fct marjlar %74,9&#8217;a ula\u015ft\u0131 ve d\u00fczeltilmi\u015f FAV\u00d6K y\u0131ll\u0131k 7,6 Milyon $ artt\u0131.<\/p>\n<h3>\u00dcr\u00fcn \u0130novasyon Hatt\u0131<\/h3>\n<p>AtriClip\u00ae FLEX-Mini\u2122 h\u0131zla benimseniyor ve Pulsed Field Ablation platformu kateter bazl\u0131 rakiplere kar\u015f\u0131 potansiyel oyun de\u011fi\u015ftirici.<\/p>\n<h3>Analist Sevgi Festivali<\/h3>\n<p>Hisseyi takip eden 9 analist\u20148 G\u00fc\u00e7l\u00fc Al, 1 Al. Ortalama fiyat hedefi 49,60 $ ve %33 y\u00fckseli\u015f potansiyeli. En son ne zaman bu kadar konsens\u00fcs g\u00f6rd\u00fcn\u00fcz?<\/p>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<p>T\u00fcm bu verileri analiz ettikten sonra i\u015fte eylem plan\u0131n\u0131z:<\/p>\n<ol>\n<li><strong>Ortalama Maliyetle Al\u0131m Yap\u0131n<\/strong> &#8211; M\u00fckemmel giri\u015f zaman\u0131n\u0131 yakalamaya \u00e7al\u0131\u015fmay\u0131n. K\u00fc\u00e7\u00fck bir pozisyonla ba\u015flay\u0131n ve 37 $ alt\u0131ndaki d\u00fc\u015f\u00fc\u015flerde ekleme yap\u0131n.<\/li>\n<li><strong>Kazan\u00e7 Uyar\u0131lar\u0131 Ayarlay\u0131n<\/strong> &#8211; Takviminize 4 Kas\u0131m&#8217;\u0131 i\u015faretleyin. Kazan\u00e7lar\u0131n tekrar beklentileri a\u015faca\u011f\u0131na inan\u0131yorsan\u0131z, kazan\u00e7 \u00f6ncesi al\u0131m yapmay\u0131 d\u00fc\u015f\u00fcn\u00fcn.<\/li>\n<li><strong>Pozisyon B\u00fcy\u00fckl\u00fc\u011f\u00fcn\u00fc Y\u00f6netin<\/strong> &#8211; Bu hala volatilitesi olan bir medikal cihaz hissesi. Toplam portf\u00f6y\u00fcn\u00fcz\u00fcn %5-10&#8217;u ile s\u0131n\u0131rlay\u0131n.<\/li>\n<li><strong>Esprili Ger\u00e7eklik Kontrol\u00fc<\/strong>: &#8220;ATRC ticareti kalp cerrahisi gibidir\u2014sakin eller kazan\u0131r. Normal volatilite s\u0131ras\u0131nda panik sat\u0131\u015f\u0131, kan g\u00f6rd\u00fc\u011f\u00fcn\u00fcz i\u00e7in ameliyathaneden ka\u00e7mak gibidir.&#8221;<\/li>\n<\/ol>\n<h2>\u2705 AtriCure, Inc. (ATRC) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<p>Bu yenilik\u00e7i medikal \u015firketi portf\u00f6y\u00fcn\u00fcze eklemeye haz\u0131r m\u0131s\u0131n\u0131z? \u0130\u015fte basit s\u00fcreciniz:<\/p>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Platformunuzu Se\u00e7in<\/td>\n<td>NASDAQ hisselerini sunan ve makul komisyon \u00fccretlerine sahip oldu\u011fundan emin olun<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesab\u0131n\u0131z\u0131 Fonlay\u0131n<\/td>\n<td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n\u2014100 $ bile ba\u015flaman\u0131z i\u00e7in yeterli<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>&#8220;ATRC&#8221; Aray\u0131n<\/td>\n<td>Sadece \u015firket ad\u0131 de\u011fil, sembol\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Emir T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td>\n<td>Giri\u015f fiyat\u0131n\u0131z\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n\u2014\u015fimdi al\u0131yorsan\u0131z yakla\u015f\u0131k 37,50 $ olarak ayarlay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>\u0130nceleyin ve Onaylay\u0131n<\/td>\n<td>Emir detaylar\u0131n\u0131 ve \u00fccretleri son kez kontrol edin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Pocket Option ATRC Ticareti \u0130\u00e7in Neden Mant\u0131kl\u0131?<\/h2>\n<p>AtriCure gibi yenilik\u00e7i \u015firketlerde pozisyon olu\u015fturmak isteyen yeni yat\u0131r\u0131mc\u0131lar i\u00e7in Pocket Option, bu stratejiyle m\u00fckemmel uyum sa\u011flayan birka\u00e7 avantaj sunar:<\/p>\n<p><strong>Minimum Para Yat\u0131rma Sadece 5 $<\/strong> &#8211; ATRC pozisyonunuzu minimum sermaye riskiyle olu\u015fturmaya ba\u015flayabilirsiniz, b\u00fcy\u00fck miktarlara ge\u00e7meden \u00f6nce yat\u0131r\u0131m tezini test etmek i\u00e7in ideal.<\/p>\n<p><strong>\u015eim\u015fek H\u0131z\u0131nda Do\u011frulama<\/strong> &#8211; Tek bir belge y\u00fckleyin ve dakikalar i\u00e7inde i\u015flem yapmaya ba\u015flay\u0131n, g\u00fcnler de\u011fil. Kazan\u00e7lar 4 Kas\u0131m&#8217;da a\u00e7\u0131klanacakken h\u0131z \u00f6nemlidir.<\/p>\n<p><strong>Esnek Para \u00c7ekme Se\u00e7enekleri<\/strong> &#8211; Kripto paralar, e-c\u00fczdanlar ve geleneksel bankac\u0131l\u0131k dahil y\u00fczlerce \u00e7ekim y\u00f6ntemiyle, ATRC analist hedeflerine ula\u015ft\u0131\u011f\u0131nda kolayca kar alabilirsiniz.<\/p>\n<p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc, medikal sekt\u00f6r haberleri ve kazan\u00e7 duyurular\u0131n\u0131 takip etmenize yard\u0131mc\u0131 olan ger\u00e7ek zamanl\u0131 grafikler ve uyar\u0131larla ATRC pozisyonunuzu izlemenizi kolayla\u015ft\u0131r\u0131r.<\/p>\n<h2>\ud83c\udf0d 2025&#8217;te AtriCure: Kalp \u0130novasyon Lideri<\/h2>\n<p>AtriCure sadece ba\u015fka bir medikal \u015firket de\u011fil\u2014d\u00fcnyan\u0131n d\u00f6rt bir yan\u0131ndaki doktorlar\u0131n kalp rahats\u0131zl\u0131klar\u0131n\u0131 tedavi etme \u015feklini devrim niteli\u011finde de\u011fi\u015ftiriyor. \u015eirket, kalp dokusunun cerrahi ablasyonu, sol atriyal apendiks y\u00f6netimi ve ameliyat sonras\u0131 a\u011fr\u0131 kontrol\u00fc i\u00e7in \u00e7\u0131\u011f\u0131r a\u00e7an cihazlar geli\u015ftiriyor.<\/p>\n<p>\u00d6nde gelen \u00fcr\u00fcnleri aras\u0131nda kalp aritmileri i\u00e7in Isolator Synergy Kelep\u00e7eleri, cryoICE Cryoablasyon Sistemi ve \u015fu anda \u015fimdiye kadar yap\u0131lm\u0131\u015f en b\u00fcy\u00fck kalp cerrahisi cihaz deneyi olan AtriClip Sistemi yer al\u0131yor.<\/p>\n<p><strong>2025 \u0130lgin\u00e7 Ger\u00e7ek:<\/strong> AtriCure&#8217;un LeAAPS deneyi 6.500 hasta kaydetti\u201413 Boeing 747 jumbo u\u00e7a\u011f\u0131 dolduracak kadar insan! Bu dev \u00e7al\u0131\u015fma, ameliyat \u00f6ncesi atriyal fibrilasyon tan\u0131s\u0131 olmayan ancak yine de fel\u00e7 riski ta\u015f\u0131yan d\u00fcnya \u00e7ap\u0131nda 1 milyondan fazla kalp cerrahisi hastas\u0131na potansiyel olarak yard\u0131mc\u0131 olabilir.<\/p>\n"},"faq":[{"question":"AtriCure hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"AtriCure hisselerini sat\u0131n almak i\u00e7in NASDAQ'da i\u015flem yapan bir arac\u0131 kurum se\u00e7in, hesab\u0131n\u0131z\u0131 fonlay\u0131n, \"ATRC\" sembol\u00fc ile arama yap\u0131n, limit emirleri kullanarak uygun fiyatla al\u0131m yap\u0131n ve i\u015flemi onaylay\u0131n."},{"question":"AtriCure'un 2025 sonu fiyat tahmini nedir?","answer":"Analistlerin konsens\u00fcs\u00fcne g\u00f6re 2025 y\u0131l sonu fiyat tahmini 43-45 $ aral\u0131\u011f\u0131nda olup, bu mevcut fiyatlardan %15-20 y\u00fckseli\u015f potansiyeli ta\u015f\u0131maktad\u0131r."},{"question":"AtriCure yat\u0131r\u0131m\u0131nda hangi riskler vard\u0131r?","answer":"Ba\u015fl\u0131ca riskler aras\u0131nda FDA onay s\u00fcre\u00e7lerindeki gecikmeler, teknoloji rekabeti, uygulama hatalar\u0131 ve y\u00fcksek de\u011ferleme nedeniyle b\u00fcy\u00fcme yava\u015flamas\u0131 yer almaktad\u0131r."},{"question":"AtriCure'un klinik deneyi neden \u00f6nemlidir?","answer":"LeAAPS deneyi 6.500 hastayla \u015fimdiye kadar yap\u0131lm\u0131\u015f en b\u00fcy\u00fck kalp cerrahisi cihaz deneyi olup, olumlu sonu\u00e7lar y\u0131lda 1 milyondan fazla ek hasta pazar\u0131n\u0131 a\u00e7abilir."},{"question":"Yeni ba\u015flayanlar AtriCure hissesi al\u0131rken nelere dikkat etmeli?","answer":"Yeni ba\u015flayanlar k\u00fc\u00e7\u00fck pozisyonlarla ba\u015flay\u0131p d\u00fc\u015f\u00fc\u015flerde ekleme yapmal\u0131, kazan\u00e7 tarihlerini takip etmeli, pozisyon b\u00fcy\u00fckl\u00fc\u011f\u00fcn\u00fc portf\u00f6y\u00fcn %5-10'u ile s\u0131n\u0131rlamal\u0131 ve panik sat\u0131\u015f\u0131ndan ka\u00e7\u0131nmal\u0131d\u0131r."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"AtriCure hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"AtriCure hisselerini sat\u0131n almak i\u00e7in NASDAQ'da i\u015flem yapan bir arac\u0131 kurum se\u00e7in, hesab\u0131n\u0131z\u0131 fonlay\u0131n, \"ATRC\" sembol\u00fc ile arama yap\u0131n, limit emirleri kullanarak uygun fiyatla al\u0131m yap\u0131n ve i\u015flemi onaylay\u0131n."},{"question":"AtriCure'un 2025 sonu fiyat tahmini nedir?","answer":"Analistlerin konsens\u00fcs\u00fcne g\u00f6re 2025 y\u0131l sonu fiyat tahmini 43-45 $ aral\u0131\u011f\u0131nda olup, bu mevcut fiyatlardan %15-20 y\u00fckseli\u015f potansiyeli ta\u015f\u0131maktad\u0131r."},{"question":"AtriCure yat\u0131r\u0131m\u0131nda hangi riskler vard\u0131r?","answer":"Ba\u015fl\u0131ca riskler aras\u0131nda FDA onay s\u00fcre\u00e7lerindeki gecikmeler, teknoloji rekabeti, uygulama hatalar\u0131 ve y\u00fcksek de\u011ferleme nedeniyle b\u00fcy\u00fcme yava\u015flamas\u0131 yer almaktad\u0131r."},{"question":"AtriCure'un klinik deneyi neden \u00f6nemlidir?","answer":"LeAAPS deneyi 6.500 hastayla \u015fimdiye kadar yap\u0131lm\u0131\u015f en b\u00fcy\u00fck kalp cerrahisi cihaz deneyi olup, olumlu sonu\u00e7lar y\u0131lda 1 milyondan fazla ek hasta pazar\u0131n\u0131 a\u00e7abilir."},{"question":"Yeni ba\u015flayanlar AtriCure hissesi al\u0131rken nelere dikkat etmeli?","answer":"Yeni ba\u015flayanlar k\u00fc\u00e7\u00fck pozisyonlarla ba\u015flay\u0131p d\u00fc\u015f\u00fc\u015flerde ekleme yapmal\u0131, kazan\u00e7 tarihlerini takip etmeli, pozisyon b\u00fcy\u00fckl\u00fc\u011f\u00fcn\u00fc portf\u00f6y\u00fcn %5-10'u ile s\u0131n\u0131rlamal\u0131 ve panik sat\u0131\u015f\u0131ndan ka\u00e7\u0131nmal\u0131d\u0131r."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AtriCure, Inc. (ATRC) Hisseleri Nas\u0131l Al\u0131n\u0131r - AtriCure, Inc. (ATRC) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-atricure\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AtriCure, Inc. (ATRC) Hisseleri Nas\u0131l Al\u0131n\u0131r - AtriCure, Inc. (ATRC) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-atricure\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-30T07:05:31+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-atricure\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-atricure\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"AtriCure, Inc. (ATRC) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; AtriCure, Inc. (ATRC) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-30T07:05:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-atricure\/\"},\"wordCount\":19,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-atricure\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals7.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-atricure\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-atricure\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-atricure\/\",\"name\":\"AtriCure, Inc. (ATRC) Hisseleri Nas\u0131l Al\u0131n\u0131r - AtriCure, Inc. (ATRC) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-atricure\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-atricure\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals7.webp\",\"datePublished\":\"2025-08-30T07:05:31+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-atricure\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-atricure\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-atricure\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals7.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals7.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-atricure\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AtriCure, Inc. (ATRC) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; AtriCure, Inc. (ATRC) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AtriCure, Inc. (ATRC) Hisseleri Nas\u0131l Al\u0131n\u0131r - AtriCure, Inc. (ATRC) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-atricure\/","og_locale":"tr_TR","og_type":"article","og_title":"AtriCure, Inc. (ATRC) Hisseleri Nas\u0131l Al\u0131n\u0131r - AtriCure, Inc. (ATRC) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-atricure\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-30T07:05:31+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-atricure\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-atricure\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"AtriCure, Inc. (ATRC) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; AtriCure, Inc. (ATRC) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-30T07:05:31+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-atricure\/"},"wordCount":19,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-atricure\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals7.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-atricure\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-atricure\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-atricure\/","name":"AtriCure, Inc. (ATRC) Hisseleri Nas\u0131l Al\u0131n\u0131r - AtriCure, Inc. (ATRC) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-atricure\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-atricure\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals7.webp","datePublished":"2025-08-30T07:05:31+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-atricure\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-atricure\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-atricure\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals7.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals7.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-atricure\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"AtriCure, Inc. (ATRC) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; AtriCure, Inc. (ATRC) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":358922,"slug":"how-to-buy-atricure","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu AtriCure, Inc. (ATRC) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu AtriCure, Inc. (ATRC)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-atricure\/"},"pt_AA":{"locale":"pt_AA","id":358919,"slug":"how-to-buy-atricure","post_title":"Como comprar a\u00e7\u00f5es da AtriCure, Inc. (ATRC) - Investimento em a\u00e7\u00f5es da AtriCure, Inc. (ATRC)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-atricure\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/358917","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=358917"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/358917\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334045"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=358917"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=358917"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=358917"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}